QR 060127
Alternative Names: QR-060127Latest Information Update: 28 Aug 2025
At a glance
- Originator Wuhan Createrna Science and Technology
- Class Analgesics; Anti-inflammatories; Antitussives; Urologics
- Mechanism of Action Transient receptor potential channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Focal segmental glomerulosclerosis; Inflammatory pain
- No development reported Cough
Most Recent Events
- 28 Aug 2025 No recent reports of development identified for phase-I development in Cough(In volunteers) in China (PO, Capsule)
- 26 May 2023 Center for Drug Evaluation (CDE) of the State Food and Drug Administration approves clinical trial application for QR 060127 in Cough (before May 2023)
- 05 Jul 2022 Phase-I clinical trials in Cough (In volunteers) in China (PO) (ChiCTR2200061875)